The Enigmatic Protein Kinase C-eta

Alakananda Basu

Department of Microbiology, Immunology & Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Alakananda.basu@unthsc.edu; Tel.: +1-817-735-2487

Received: 17 January 2019; Accepted: 10 February 2019; Published: 13 February 2019

Abstract: Protein kinase C (PKC), a multi-gene family, plays critical roles in signal transduction and cell regulation. Protein kinase C-eta (PKC_\eta) is a unique member of the PKC family since its regulation is distinct from other PKC isozymes. PKC_\eta was shown to regulate cell proliferation, differentiation and cell death. It was also shown to contribute to chemoresistance in several cancers. PKC_\eta has been associated with several cancers, including renal cell carcinoma, glioblastoma, breast cancer, non-small cell lung cancer, and acute myeloid leukemia. However, mice lacking PKC_\eta were more susceptible to tumor formation in a two-stage carcinogenesis model, and it is downregulated in hepatocellular carcinoma. Thus, the role of PKC_\eta in cancer remains controversial. The purpose of this review article is to discuss how PKC_\eta regulates various cellular processes that may contribute to its contrasting roles in cancer.

Keywords: protein kinase C; PKC_\eta; cell proliferation; differentiation; senescence; apoptosis; drug resistance; tumor promotion; tumor suppression

1. Introduction

Intricate regulation of cellular signaling systems is critical for the proper functioning of cells. Consequently, a deregulation in signal transduction pathways can lead to many human diseases. Protein kinase C (PKC), a family of serine/threonine protein kinases, plays critical roles in signal transduction and cell regulation [1]. The identification of PKC as a receptor for tumor-promoting phorbol esters, which are potent activators of PKC and can substitute for the physiologic stimulator diacylglycerol (DAG) established a link between PKC and cancer [2].

PKC constitutes a multi-gene family that could be categorized into three groups based on their structural variations and biochemical properties [3]. The classical or conventional (c) PKCs (\(\alpha, \beta_I, \beta_{II}, \gamma\)) require Ca^{2+} and DAG/phorbol esters for their activities. The novel (n) (\(\delta, \varepsilon, \eta, \theta\)) PKCs are insensitive to Ca^{2+} but respond to DAG/phorbol esters. The atypical (a) PKCs (\(\xi, \iota\)) are insensitive to both Ca^{2+} and DAG/phorbol esters. While the physiological stimulator DAG causes transient activation of conventional and novel PKCs, the tumor-promoting phorbol esters cause persistent activation [3]. Activation of PKCs induces their translocation to the membrane followed by their degradation or downregulation [4].

The regulation of PKC_\eta, a member of the novel PKC family, is unique [3]. Although PKC_\eta is most closely related to PKC_\epsilon [5,6], there are variations in the lipid-binding site [7]. It is the only PKC that is activated by cholesterol sulfate and sulfatide [8]. It is also resistant to translocation and downregulation when stimulated with phorbol esters or cholesterol sulfate [9,10]. In fact, we and others have shown that PKC_\eta is upregulated by the tumor-promoting phorbol esters [11–14] as well as several structurally and functionally distinct PKC activators [13].

The expression of PKC_\eta is also unique compared to other PKC isozymes [15,16]. It was isolated from cDNA libraries of mouse epidermis [5] and human keratinocytes [15]. PKC_\eta mRNA was most abundant in lung tissues and was also detected in skin and heart tissues [15]. Contrary to other PKC
isozymes, the expression of PKCη in the brain was low [15,16]. It was shown to be predominantly expressed in the epidermis of mouse skin and epithelia of the digestive and respiratory tracts, including the tongue, esophagus, forestomach, glandular stomach, intestine, colon, trachea and, bronchus [16].

PKCη plays critical roles in cell proliferation, differentiation and cell death, as seen in Figure 1 [3,8,17]. There are, however, controversies regarding its role in tumor promotion versus tumor suppression. The present review article summarizes how PKCη regulates various cellular processes that may impact on its contrasting roles in cancer.

![Diagram of protein kinase C-eta (PKCη)](image)

**Figure 1.** Various functions of protein kinase C-eta (PKCη).

2. Regulation of Cell Proliferation

The most consistent function of PKCη is its ability to regulate cell cycle progression. The cell cycle is regulated primarily by the tumor suppressor protein Rb and cyclin-dependent kinases (CDK). While phosphorylation and inactivation of Rb by CDKs is needed to allow cell cycle progression, the inhibition of Rb phosphorylation by CDK inhibitors, such as p16, p21 and p27 causes cell cycle arrest [18].

Interestingly, both activation and inhibition of PKCη have been reported to cause cell cycle arrest (Table 1). Livneh et al. first reported that ectopic expression of PKCη in NIH3T3 cells inhibits Rb phosphorylation and induces CDK inhibitors p21 and p27, causing cell cycle arrest [19]. Overexpression of PKCη also inhibited cell growth in keratinocytes but in this study, PKCη overexpression had no effect on cell growth in either human or mouse fibroblasts [20]. On the other hand, Nomoto et al. showed that overexpression of PKCη in NIH3T3 cells induced anchorage-independent growth [21]. The reason for the distinct effects of PKCη overexpression on cell growth in NIH3T3 fibroblasts is not clear except different methods were used to monitor fibroblast cell growth. For example, while Livneh et al. [19] examined how PKCη affects cell cycle progression by analyzing different phases of the cell cycle by flow cytometric analysis, Ohba et al. [20] monitored cell growth by MTT assay, and Nomoto et al. [21] compared the colony forming ability of NIH3T3 cells transfected with either PKCη or a control vector in soft agar.

Kashiwagi et al. provided a mechanistic explanation that association of PKCη with cyclin E/Cdk2/p21 complex causes phosphorylation of p21 at Ser146 site and dephosphorylation of Thr160 of Cdk2 resulting in inhibition of Cdk2 activity and G1 arrest in keratinocytes [8,22]. Subsequently, Livneh and co-workers confirmed that PKCη also forms complexes with cyclin E/Cdk2 in NIH3T3 and MCF-7 cells, and this complex formation was most prominent in serum-starved cells and could be visualized in the perinuclear region [23]. However, PKCη overexpression had opposite effects on cell growth in NIH3T3 versus MCF-7 cells. In contrast to NIH3T3 cells where PKCη overexpression was shown to inhibit cell growth [19], induced expression of PKCη in MCF-7 cells promoted cell growth [24]. Overexpression of PKCη caused an increase in both p21 and p27 in NIH3T3 cells [19] but p27 was not altered in MCF-7 cells [24]. Thus, an increase in p27 may be required for cell growth inhibition in MCF-7 cells. Consistent with this notion, we recently observed that knockdown of PKCη decreased clonogenic survival of breast cancer MCF-7 and T47D cells and this was associated with an increase in p27 [25]. Hara et al. showed that p27 mRNA was downregulated in PKCη-null keratinocytes grown in 3D organotypic culture [26]. While an increase in p27 was associated with cell growth inhibition in both keratinocytes [26] and breast cancer cells [25], depletion of PKCη caused a
decrease in p27 in keratinocytes [26] but an increase in p27 in breast cancer cells [25]. It is not clear why PKC\(\eta\) had opposite effects on p27 in keratinocytes versus breast cancer cells, however, it reinforces the notion that PKC\(\eta\) functions in a context-dependent manner.

An increase in PKC\(\eta\) was shown to be responsible for the anti-leukemic effects of IFN\(\alpha\) in chronic myeloid leukemia cells [27]. PKC\(\eta\) overexpression caused cell cycle arrest in normal and leukemic human myeloid cells but had no effect on erythroid progenitor cells [27]. PKC\(\eta\) was shown to promote cell proliferation in glioblastoma cells by acting upstream of Akt and mTOR signaling pathways [28]. Knockdown of PKC\(\eta\) inhibited cell cycle progression in B lymphoma cells, suggesting a growth-promoting effect of PKC\(\eta\) [29]. Thus, the function of PKC\(\eta\) on cell proliferation varies significantly with cell types (Table 1).
| Tissue/Tumor Type     | Cell Line     | Expression  | Phenotype                                         | Potential Mechanism                                                                                   | Reference |
|----------------------|---------------|-------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------|
| Fibroblasts          | NIH3T3        | WT-PKC\(\eta\) | Cell cycle arrest, adipogenesis                   | ↑ p21, 27 & cyclin E; ↓ Rb phosphorylation                                                             | [19]      |
|                      | NIH3T3        | WT-PKC\(\eta\) | Anchorage-independent growth                      |                                                                                                       | [21]      |
|                      | NIH3T3 & NHF  | WT-PKC\(\eta\) | No effect on cell growth                          |                                                                                                       | [20]      |
| Keratinocytes        | NHK           | WT-PKC\(\eta\) | Growth arrest, terminal differentiation            | ↑ p21 Phosphorylation; ↓ Cdk2, ↑ TGase 1                                                             | [20,22]   |
|                      | NHK           | WT-PKC\(\eta\) | Differentiation                                    | ↑ Loricrin                                                                                             | [30]      |
|                      | NHEK          | WT-PKC\(\eta\) | Differentiation                                    | Binding and activation of RalA                                                                       | [31]      |
| Mouse keratinocytes  | PKC\(\eta\)-null |             | Delayed growth arrest & terminal differentiation    | ↑ JNK/cJun, ↓ p27                                                                                      | [26]      |
| Keratinocytes        | NHK           | WT-PKC\(\eta\) | Growth arrest, differentiation                     | ↓ UV-induced p38 MAPK activity                                                                       | [33]      |
| Adenoid cystic carcinoma | ACC-2 & ACC-M | WT-PKC\(\eta\) | Suppressed cisplatin-induced apoptosis             | ↓ p53/p21                                                                                             | [34]      |
| Breast cancer        | MCF-7, T47D   | PKC\(\eta\) siRNA | Decreased clonogenic survival, induced senescence | ↑ p27                                                                                                  | [25]      |
|                      | MCF-7         | PKC\(\eta\) shRNA | Decreased H2O2 and etoposide-induced senescence    | ↓ p21, p27 & IL-6; ↑ IL-8                                                                            | [35]      |
|                      | MCF-7         | WT-PKC\(\eta\) | Protects against TNF-induced apoptosis             |                                                                                                       | [36]      |
|                      | MCF-7         | WT-PKC\(\eta\) | Protects against UVC- and CPT-induced apoptosis    | ↓ JNK activity                                                                                         | [37]      |
|                      | MCF-7         | WT-PKC\(\eta\) | Protects against CPT-induced apoptosis             | ↑ NF-κB activity                                                                                        | [38]      |
| Glioblastoma         | U-251 GBM     | PKC\(\eta\)-KR | Decreased cell proliferation                      | ↓ Akt, mTOR activity                                                                                  | [28]      |
|                      | U-1242 MG     | WT-PKC\(\eta\) | Increased cell proliferation                      | ↑ ERK/Elk-1 activity                                                                                   | [39]      |
| Leukemia             | CML-derived KT1 | Peptide inhibitor | Suppression of IPN-dependent cell cycle arrest |                                                                                                       | [27]      |
| CD34+ progenitor     | PKC\(\eta\) siRNA | Increase in clonogenic survival                     |                                                                                                       | [27]      |
| CD34+ progenitor     | CA-PKC\(\eta\) | Inhibition of cell growth, no effect on apoptosis   |                                                                                                       | [27]      |
| CML K562             | WT-PKC\(\eta\) | IM resistance                                     | ↑ Raf/MEK/ERK signaling and CRAF                                                                      | [41]      |
| CML stem cells       | PKC\(\eta\) shRNA | Sensitized to IM                                  |                                                                                                       | [41]      |
| Lymphoma             | IM-9, EBV+ B cells | PKC\(\eta\) siRNA | Cell cycle arrest                                 | ↑ TAp73, p21, p38 MAPK; ↓ Cdk5                                                                    | [29]      |
|                      | IM9           | PKC\(\eta\) siRNA | Sensitized to BTZ and SRF                          |                                                                                                       | [29]      |
|                      | L428          | PKC\(\eta\) shRNA | Sensitized to doxorubicin- and CPT-induced apoptosis |                                                                                                       | [42]      |
| Lung cancer          | A549          | PKC\(\eta\)-antisense                            | Increased vincristine and paclitaxel-induced apoptosis                                                | [43]      |
| Prostate cancer      | PC3           | PKC\(\eta\)-antisense                            | Increased TRAIL-induced apoptosis                                                                   | [44]      |
| Mesenchymal stem cells | hMSC         | PKC\(\eta\)-C2                                    | chondrogenic differentiation                                                                       | Increase in collagen type II                                                                          | [45]      |
3. Regulation of Differentiation

Most of the earlier studies associated growth inhibitory effects of PKC\(\eta\) with its ability to trigger differentiation partly because PKC\(\eta\) was most abundant in epithelial tissues [46], was expressed during epidermal differentiation [47] and was shown to be localized in differentiating or differentiated epithelial cells [16]. Moreover, cholesterol sulfate, a metabolite of cholesterol generated during squamous differentiation caused marked stimulation of PKC\(\eta\) activity [48]. PKC\(\eta\) levels were increased both at the soluble and particulate fractions of primary mouse keratinocytes during calcium-induced differentiation [49].

Several studies investigated potential mechanisms by which PKC\(\eta\) triggers keratinocyte differentiation. Ohba et al. [20] demonstrated that overexpression of PKC\(\eta\) in human and mouse keratinocytes but not in fibroblasts enhanced the expression and activity of transglutaminase 1, a key enzyme involved in squamous cell differentiation. PKC\(\eta\) was shown to associate with and activate the Src kinase family member Fyn, which is required for normal keratinocyte differentiation [32]. Overexpression of Fyn enhanced the expression of CDK inhibitors p21 and p27, induced the differentiation marker transglutaminase, and suppressed the growth of keratinocytes but had no effect in dermal fibroblasts [32]. These results provided an explanation why PKC\(\eta\) induced differentiation in keratinocytes but not in fibroblasts. PKC\(\eta\) also increased JunD-mediated transcription of loricrin, which is expressed at the late stage of keratinocyte differentiation [30]. The small G protein RaLA was shown to interact with PKC\(\eta\) resulting in the activation of RaLA and the induction of keratinocyte differentiation [31]. Hara et al. [26] demonstrated that growth arrest and terminal differentiation were delayed in PKC\(\eta\)-null keratinocytes and this was associated with downregulation of p27 mRNA via c-Jun N-terminal kinase (JNK) signaling. Re-expression of PKC\(\eta\) or suppression of JNK/c-Jun signaling caused upregulation of p27 mRNA resulting in cell cycle arrest and terminal differentiation [26]. Overexpression of the C2 domain of PKC\(\eta\) increased the expression of collagen type II, and led to chondrogenic differentiation in mesenchymal stem cells [45]. Thus, an association between inhibition of cell proliferation and differentiation was established.

4. Regulation of Apoptosis

Apoptosis is a physiologic form of cell death required to maintain tissue homeostasis. Lack of cell death by apoptosis can lead to cancer. In addition, since many cancer chemotherapeutic drugs kill cancer cells by inducing apoptosis, a defect in apoptotic signaling pathways can contribute to chemoresistance. There are two major pathways of cell death: the extrinsic or receptor-initiated pathway and the intrinsic or mitochondrial pathway. The extrinsic pathway is triggered by binding of ligands to the tumor necrosis factor-\(\alpha\) (TNF) receptor superfamily, whereas cytotoxic chemotherapeutic drugs primarily utilize the intrinsic pathway. While activation of caspases induces apoptosis, pro- and anti-apoptotic Bcl-2 family members regulate apoptosis.

We observed that several different PKC activators protected against TNF-induced apoptosis whereas the PKC-specific inhibitor bisindolylmaleimide II enhanced apoptosis in breast cancer MCF-7 cells [11]. Since PKC\(\eta\) is the only PKC isozyme upregulated by PKC activators and downregulated by the PKC inhibitor bisindolylmaleimide II, this study implicated PKC\(\eta\) in protecting against TNF-induced apoptosis [4]. Beck et al. showed that there was a correlation between the upregulation of multiple drug resistance-associated genes and PKC\(\eta\) expression in specimens derived from sixty-four primary breast cancer patients, implicating PKC\(\eta\) in anticancer drug resistance [50]. While these results are correlative, we showed that ectopic expression of PKC\(\eta\) in MCF-7 cells protected against TNF-induced apoptosis [36]. Subsequently, it was shown that PKC\(\eta\) protects against apoptosis induced by UV and gamma irradiation in glioblastoma cell lines [40]. Downregulation of PKC\(\eta\) by anti-sense oligonucleotides (ODN) enhanced vincristine- and paclitaxel-induced apoptosis in A549 lung cancer cells [43] and TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in prostate cancer PC3 cells [44]. PKC\(\eta\) levels were higher in Hodgkin’s lymphoma (HL)-derived L428 cells that are resistant to doxorubicin and camptothecin (CPT) compared to drug-sensitive KMH2 cells, and knockdown
of PKC\(\eta\) by siRNA in L428 cells sensitized them to these drugs [42]. In addition, PKC\(\eta\) suppressed and shR-PKC\(\eta\) promoted cisplatin-induced apoptosis in adenoid cystic carcinoma (ACC) cells [34]. These results suggest that PKC\(\eta\) may confer resistance to anticancer therapy.

Several studies explored the mechanisms by which PKC\(\eta\) regulates apoptosis. Overexpression of wild-type PKC\(\eta\) inhibited and dominant-negative PKC\(\eta\) enhanced UVB-induced apoptosis in normal human keratinocytes (NHK) [33]. UV-induced activation of p38 MAP kinase suppressed caspase-3 activity in NHK, and this was blocked by dominant-negative PKC\(\eta\), suggesting that PKC\(\eta\) negatively regulates UV-induced apoptosis in NHK cells via the p38 MAP kinase pathway [33]. In MCF-7 breast cancer cells, PKC\(\eta\) was shown to protect against DNA damaging agents, such as UVC irradiation and anticancer drug CPT by suppressing JNK activity [37]. PKC\(\eta\) also protected against CPT via activation of NF-\(\kappa\)B, leading to the induction of anti-apoptotic Bcl-2 in MCF-7 cells [38].

Akt, mTOR and mitogen-activated protein kinase (MAPK) pathways are known to promote cell survival. There are, however, controversies regarding how PKC\(\eta\) regulates the Akt signaling pathway. While Aeder et al. reported that PKC\(\eta\) activates both Akt and mTOR pathways in glioblastoma cells [28], Shahaf et al. reported that PKC\(\eta\) negatively regulates Akt in MCF-7 cells [51]. In the latter study, Akt activation was monitored in response to IGF-1 or insulin stimulation [51].

Development of resistance to the BCR-ABL inhibitor imatinib mesylate (IM) is a significant problem in the treatment of chronic myelogenous leukemia (CML). Upregulation of PRKCH, the gene encoding PKC\(\eta\), was identified as one mechanism contributing to IM resistance independent of any mutation in BCR-ABL [41]. PRKCH was elevated in IM-resistant CML patient samples and CML stem cells [41]. The mechanism by which PKC\(\eta\) contributed to IM resistance involved activation of the RAF/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling via phosphorylation/activation of CRAF [41]. We have recently shown that knockdown of PKC\(\eta\) in breast cancer cells led to the downregulation of the anti-apoptotic Bcl-2 family protein Mcl-1 via the ubiquitin proteasome-mediated pathway [52]. Knockdown of PKC\(\eta\) inhibited ERK1/2 phosphorylation but knockdown of ERK1, but not ERK2, decreased Mcl-1 levels in MCF-7 cells. Moreover, overexpression of ERK1 rescued the effect of PKC\(\eta\) knockdown on Mcl-1 downregulation [52]. These results suggest that PKC\(\eta\) functions upstream of ERK1 in MCF-7 breast cancer cells.

5. Regulation of Senescence

Cellular senescence is defined as a permanent arrest of proliferative cells that are metabolically active [53]. The consequences of senescence could be beneficial or detrimental depending on the cellular context, the nature of the stimulus and the state of senescence [54–56]. Senescence can cause tumor suppression by inducing permanent cell cycle arrest and by recruiting immune systems to clear senescent cells [57,58]. However, senescent cells can also contribute to tumor progression and relapse. Senescence-associated secretory phenotype (SASP), which is associated with the secretion of growth factors, pro-inflammatory cytokines, chemokines, and matrix remodeling enzymes, could facilitate tumor growth under certain cellular contexts [57,59].

Zurgil et al. reported that PKC\(\eta\) promotes senescence in MCF-7 breast cancer cells in response to oxidative stress and etoposide-induced DNA damage [35]. In contrast, we found that knockdown of PKC\(\eta\) induced senescence in breast cancer MCF-7 and T47D cells [25]. The apparent discordant results could be partly explained by the differences in experimental design. In the study by Zurgil et al., high concentrations of H\(_2\)O\(_2\) (150 \(\mu\)M) or etoposide (400 \(\mu\)M) caused a substantial increase in senescence, which was attenuated by PKC\(\eta\) knockdown [35]. In fact, knockdown of PKC\(\eta\) by itself caused a modest but significant increase in cellular senescence [35], and this was consistent with our results [25]. shRNA-mediated knockdown of PKC\(\eta\) had little effect on p27 and p21 but attenuated the increase in p21 and p27 by etoposide [35]. In addition, PKC\(\eta\) knockdown increased IL-6 secretion but suppressed IL-8 secretion [35]. It is not clear why PKC\(\eta\) had opposite effects on these pro-inflammatory cytokines both of which are associated with SASP. We found that silencing of PKC\(\eta\) by siRNA caused
a substantial increase in p27 in both MCF-7 and T47D cells [25]. Moreover, silencing of p27 attenuated senescence induced by PKC\(\eta\) knockdown [25], suggesting upregulation of p27 as one mechanism contributing to the induction of senescence caused by PKC\(\eta\) deficiency.

6. Tumor Suppression by PKC\(\eta\)

Canzian et al. first reported that PKC\(\eta\) is decreased by 5- to 10-fold in murine lung tumors compared to normal murine lung [60], suggesting that a decrease in PKC\(\eta\) may be associated with lung carcinogenesis. A clue to the tumor suppressive role of PKC\(\eta\) came from the observation that cholesterol sulfate, which acts as a second messenger of PKC\(\eta\) and induced squamous differentiation, inhibited skin carcinogenesis when applied prior to tumor-promoting phorbol ester TPA. This suggests that PKC\(\eta\) inhibits the promotional phase of skin carcinogenesis [61]. Further evidence regarding the tumor suppressive role of PKC\(\eta\) came from the observation that PKC\(\eta\)-knockout mice were more sensitive to tumor formation in a two-stage carcinogenesis model compared to wild-type mice [62]. The ability of PKC\(\eta\) to inhibit tumor promotion was associated with its ability to induce differentiation in keratinocytes [8].

The possible tumor suppressive role of PKC\(\eta\) was also investigated by analyzing human tissue samples. PKC\(\eta\) mRNA was significantly lower in colon tumors compared to normal mucosa samples [63]. PKC\(\eta\) expression was decreased in locally invasive breast tumor tissues compared to the surrounding normal epithelium, suggesting that PKC\(\eta\) is decreased during later stages of transformation [64]. Overexpression of PKC\(\eta\) was shown to exert anti-leukemic responses in chronic myeloid leukemia cells by inhibiting cell cycle progression of myeloid progenitor growth via type 1 interferon receptor [27]. PKC\(\eta\) expression was decreased in 82% of hepatocellular carcinoma (HCC) tissues compared to adjacent normal tissues and was associated with poorer long-term survival of HCC patients [65].

7. Tumor Promotion by PKC\(\eta\)

Overexpression of PKC\(\eta\) in NIH3T3 cells was shown to induce anchorage-independent growth [21], suggesting that PKC\(\eta\) may also contribute to tumor progression. A correlation between PKC\(\eta\) expression and tumor progression was noted in renal cell carcinoma (RCC) [66]. PKC\(\eta\) was shown to promote proliferation of malignant astrocytoma and glioblastoma but not non-malignant astrocytes [28,39]. PKC\(\eta\) levels were high in EBV-transformed B cells and EBV-positive B cells, such as Raji, Daudi and IM-9 cells but not in normal B cells [29]. We have shown that PKC\(\eta\) levels were increased with the aggressiveness of breast cancer in the progressive MCF-10A series, and knockdown of PKC\(\eta\) attenuated breast cancer cell growth [25,67]. Increased PKC\(\eta\) expression was associated with poor prognosis in non-small cell lung cancer patients [68]. It has been reported that the microRNA (miRNA) miR-24-3p functions as a tumor suppressor in human lacrimal adenoid cystic carcinoma (LACC) via the p53/p21 pathway by downregulating PKC\(\eta\), and overexpression of PKC\(\eta\) rescued the tumor suppressive function of miR-24-3p by downregulating p53 [34]. PKC\(\eta\) levels were higher in LACC tissues compared to adjacent non-tumor tissues and overexpression of miR-24-3p decreased PKC\(\eta\) mRNA and protein levels [34]. PKC\(\eta\) contributed to the malignant phenotype of ACC cells by enhancing cell proliferation, migration and invasion and by inhibiting apoptosis [34]. The \(PKRCH\) gene was highly expressed in hematopoietic stem cells (HSC) and leukemia stem cells (LSC) [69]. PKC\(\eta\) expression was also associated with poor prognosis in acute myeloid leukemia (AML) patients, although it was not required for the development of AML [69].

8. Conclusions

The function of PKC\(\eta\) varies significantly with cell types (Table 1). Several laboratories showed that PKC\(\eta\) induced terminal differentiation in keratinocytes [8,20,26,31,32] and PKC\(\eta\)-null mice were more susceptible to tumor formation [61,62]. In contrast, there were controversies regarding the role of PKC\(\eta\) in NIH3T3 fibroblasts [19–21]. The transcriptional regulation of PKC\(\eta\) [70] as well
as the regulation of downstream signaling of PKCη [32] appear to be distinct in keratinocytes versus fibroblasts.

Caution should be exercised in interpreting the function of PKCη in various systems. Some of the studies that implicated PKCη in tumor promotion versus tumor suppression are correlative, and the number of tumor samples analyzed to definitively assess the function of PKCη may not be adequate. In studies involving genetic manipulation of PKCη, it is important to consider the methods used to manipulate PKCη, the selection pressure and the extent of PKCη knockdown/overexpression, all of which may affect the outcome of the results. The specificity of the antibodies used to detect total and phosphorylated PKCη should also be carefully determined.

It is also important to recognize the complexity of the cellular signaling systems. For example, a decrease in cell proliferation may also promote epithelial-to-mesenchymal transition and is associated with increased malignancy [71]. This may explain why overexpression of PKCη inhibited cell growth [19] but enhanced anchorage-independent growth [21] in NIH3T3 cells. Similarly, a decrease in cell growth is often associated with an increase in cell death by apoptosis. However, inhibition of cell proliferation may also restrict the ability of conventional chemotherapeutic drugs that target actively proliferating cells to kill cancer cells. This is consistent with our observation that the induction of senescence caused by PKCη knockdown was associated with a decrease in doxorubicin-induced apoptosis [25]. In addition, while overexpression of PKCη inhibited cell growth in NHK [8,20,26,31,32], PKCη overexpression inhibited UVB-induced apoptosis in these cells [33].

PKCη interacts with several signaling pathways and the status of these pathways will influence the function of PKCη. The ability of PKCη to regulate cellular senescence may also contribute to its contrasting roles in cancer since depending on the cellular context, cellular senescence may promote or suppress cancer. Thus, a thorough understanding of how PKCη regulates various cellular processes is essential prior to exploiting this enigmatic PKC family member for cancer therapy.

Funding: This research received no external funding.

Acknowledgments: The author wishes to thank Deepanwita Pal for critical reading of the manuscript.

Conflicts of Interest: The author declares no conflict of interest.

Abbreviations

| Abbrev. | Definition |
|---------|------------|
| ACC     | adenoid cystic carcinoma |
| AML     | acute myelocytic leukemia |
| Bcl-2   | B-cell lymphoma 2 |
| Btz     | bortezomib |
| CDK     | cyclin-dependent kinase |
| CML     | chronic myelogenous leukemia |
| CPT     | camptothecin |
| DAG     | diacylglycerol |
| DN      | dominant-negative |
| EGFR    | epidermal growth factor receptor |
| ERK     | extracellular signal-regulated kinase |
| GBM     | glioblastoma multiforme |
| HSC     | hematopoietic stem cells |
| IFN     | Interferon-α |
| IM      | imatinib mesylate |
| JNK     | c-Jun N-terminal kinase |
| LSC     | leukemia stem cells |
| MAPK    | mitogen-activated protein kinase |
| Mcl-1   | myeloid cell leukemia 1 |
| mTOR    | mechanistic target of rapamycin |
| MTT     | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
NF-κB nuclear factor-κB
NHEK normal human epidermal keratinocytes
NHF normal human fibroblasts
NHK normal human keratinocytes
ODN oligonucleotide
PKC protein kinase C
SASP senescence-associated secretory phenotype
SRF Sorafenib
TNF tumor necrosis factor-α
TGase 1 transglutaminase 1
TPA 12-O-tetradecanoylphorbol-13-acetate
TRAIL TNF-related apoptosis-inducing ligand
WT wild-type

References
1. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. *Nature* 1984, 308, 693–698. [CrossRef] [PubMed]
2. Blumberg, P.M. Protein kinase C as the receptor for the phorbol ester tumor promoters: Sixth Rhoads memorial award lecture. *Cancer Res.* 1988, 48, 1–8. [PubMed]
3. Pal, D.; Basu, A. The unique protein kinase Ceta: Implications for breast cancer (review). *Int. J. Oncol.* 2014, 45, 493–498. [CrossRef] [PubMed]
4. Basu, A. The potential of protein kinase C as a target for anticancer treatment. *Pharmacol. Ther.* 1993, 59, 257–280. [CrossRef]
5. Osada, S.; Mizuno, K.; Saido, T.C.; Akita, Y.; Suzuki, K.; Kuroki, T.; Ohno, S. A phorbol ester receptor/protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin. *J. Biol. Chem.* 1990, 265, 22434–22440. [PubMed]
6. Kazanietz, M.G.; Areces, L.B.; Bahador, A.; Mischak, H.; Goodnight, J.; Mushinski, J.F.; Blumberg, P.M. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. *Mol. Pharmacol.* 1993, 44, 298–307.
7. Littler, D.R.; Walker, J.R.; She, Y.M.; Finerty, P.J., Jr.; Newman, E.M.; Dhe-Paganon, S. Structure of human protein kinase C eta (PKCeta) C2 domain and identification of phosphorylation sites. *Biochem. Biophys. Res. Commun.* 2006, 349, 1182–1189. [CrossRef]
8. Kashiwagi, M.; Ohba, M.; Chida, K.; Kuroki, T. Protein kinase C eta (PKC eta): Its involvement in keratinocyte differentiation. *J. Biochem.* 2002, 132, 853–857. [CrossRef]
9. Murakami, A.; Chida, K.; Suzuki, Y.; Kikuchi, H.; Imajoh-Ohmi, S.; Kuroki, T. Absence of down-regulation and translocation of the eta isoform of protein kinase C in normal human keratinocytes. *J. Investig. Dermatol.* 1996, 106, 790–794. [CrossRef]
10. Chida, K.; Sagara, H.; Suzuki, Y.; Murakami, A.; Osada, S.; Ohno, S.; Hirosawa, K.; Kuroki, T. The eta isoform of protein kinase C is localized on rough endoplasmic reticulum. *Mol. Cell. Biol.* 1994, 14, 3782–3790. [CrossRef]
11. Basu, A. The involvement of novel protein kinase C isoforms in influencing sensitivity of breast cancer MCF-7 cells to tumor necrosis factor-alpha. *Mol. Pharmacol.* 1998, 53, 105–111. [CrossRef] [PubMed]
12. Chen, C.C.; Wang, J.K.; Chen, W.C. TPA induces translocation but not down-regulation of new PKC isoform eta in macrophages, MDCK cells and astrocytes. *FEBS Lett.* 1997, 412, 30–34. [CrossRef]
13. Pal, D.; Outram, S.P.; Basu, A. Novel regulation of protein kinase C- eta. *Biochem. Biophys. Res. Commun.* 2012, 425, 836–841. [CrossRef] [PubMed]
14. Resnick, M.S.; Luo, X.; Vinton, E.G.; Sando, J.J. Selective up-regulation of protein kinase C eta in phorbol ester-sensitive versus -resistant EL4 mouse thymoma cells. *Cancer Res.* 1997, 57, 2209–2215. [PubMed]
15. Bacher, N.; Zisman, Y.; Berent, E.; Livneh, E. Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart. *Mol. Cell. Biol.* 1991, 11, 126–133. [CrossRef] [PubMed]
16. Osada, S.; Hashimoto, Y.; Nomura, S.; Kohno, Y.; Chida, K.; Tajima, O.; Kubo, K.; Akimoto, K.; Koizumi, H.; Kitamura, Y.; et al. Predominant expression of nPKC eta, a Ca(2+)-independent isofrom of protein kinase C in epithelial tissues, in association with epithelial differentiation. *Cell Growth Differ*. 1993, 4, 167–175. [PubMed]

17. Zurgil, U.; Ben-Ari, A.; Rotem-Dai, N.; Karp, G.; Krasnitsky, E.; Frost, S.A.; Livneh, E. PKC eta is an anti-apoptotic kinase that predicts poor prognosis in breast and lung cancer. *Biochem. Soc. Trans.* 2014, 42, 1519–1523. [CrossRef] [PubMed]

18. Maddika, S.; Ande, S.R.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zure, A.; Eshraghi, M.; Manda, K.D.; Wieche, E.; Lo, M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. *Drug Resist. Update* 2007, 10, 13–29. [CrossRef] [PubMed]

19. Livneh, E.; Shimoni, T.; Bechor, E.; Doki, Y.; Schieren, I.; Weinstein, J.B. Linking protein kinase C to cell cycle: Ectopic expression of PKC eta in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis. *Oncogene* 1996, 12, 1545–1555. [PubMed]

20. Ohba, M.; Ishino, K.; Kashiwagi, M.; Kawabe, S.; Chida, K.; Huh, N.H.; Kuroki, T. Induction of differentiation in normal human keratinocytes by adenovirus-mediated introduction of the eta and delta isoforms of protein kinase C. *Mol. Cell. Biol.* 1998, 18, 5199–5207. [CrossRef] [PubMed]

21. Nomoto, S.; Watanabe, Y.; Ninomiya-Tsuji, J.; Yang, L.X.; Nagai, Y.; Kiuchi, K.; Hagiwara, M.; Hitada, H.; Matsumoto, K.; Irie, K. Functional analyses of mammalian protein kinase C isozymes in budding yeast and mammalian fibroblasts. *Genes Cells* 1997, 2, 601–614. [CrossRef] [PubMed]

22. Kashiwagi, M.; Ohba, M.; Watanabe, H.; Ishino, K.; Kasahara, K.; Sanai, Y.; Taya, Y.; Kuroki, T. PKC eta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes. *Oncogene* 2000, 19, 6334–6341. [PubMed]

23. Shtutman, M.; Hershko, T.; Maimel, A.; Fima, E.; Livneh, E. PKC eta associates with cyclin E/Cdk2 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes. *Oncogene* 2000, 19, 6303–6309. [CrossRef] [PubMed]

24. Fima, E.; Shtutman, M.; Libros, P.; Maimel, A.; Shahaf, G.; Kahana, G.; Livneh, E. PKC eta enhances cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells. *Oncogene* 2001, 20, 6794–6804. [CrossRef] [PubMed]

25. Basu, A.; Pal, D.; Blaydes, R. Differential effects of protein kinase C-eta on apoptosis versus senescence. *Cell. Signal.* 2018, 55, 1–7. [CrossRef] [PubMed]

26. Hara, T.; Miyazaki, M.; Hakuno, F.; Takahashi, S.; Chida, K. PKC eta promotes a proliferation to differentiation switch in keratinocytes via upregulation of p27Kip1 mRNA through suppression of JNK/c-Jun signaling under stress conditions. *Cell Death Dis.* 2011, 2, e157. [CrossRef]

27. Redig, A.J.; Sassano, A.; Majchrzak-Kita, B.; Katsoulidis, E.; Liu, H.; Altman, J.K.; Fish, E.N.; Wickrema, A.; Platanias, L.C. Activation of protein kinase C eta by type I interferons. *J. Biol. Chem.* 2009, 284, 10301–10314. [CrossRef]

28. Aeder, S.E.; Martin, P.M.; Suh, J.W.; Hussain, I.M. PKC eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. *Oncogene* 2004, 23, 9062–9069. [CrossRef] [PubMed]

29. Park, G.B.; Choi, Y.; Kim, Y.S.; Lee, H.K.; Kim, D.; Hur, D.Y. Silencing of PKC eta induces cycle arrest of UV-induced activation of caspase-3 in normal human keratinocytes. *Biochem. Biophys. Res. Commun.* 2003, 303, 350–356. [CrossRef]
34. Zhang, M.X.; Zhang, J.; Zhang, H.; Tang, H. miR-24-3p Suppresses Malignant Behavior of Lacrimal Adenoid Cystic Carcinoma by Targeting PRKCH to Regulate p53/p21 Pathway. *PLoS ONE* **2016**, *11*, e0158433. [CrossRef] [PubMed]

35. Zurgil, U.; Ben-Ari, A.; Atlas, K.; Isakov, N.; Apte, R.; Livneh, E. PKC eta promotes senescence induced by oxidative stress and chemotherapy. *Cell Death Dis.* **2014**, *5*, e1531. [CrossRef] [PubMed]

36. Akkaraju, G.R.; Basu, A. Overexpression of protein kinase C-eta attenuates caspase activation and tumor necrosis factor-alpha-induced cell death. *Biochem. Biophys. Res. Commun.* **2000**, *279*, 103–107. [CrossRef] [PubMed]

37. Rotem-Dai, N.; Oberkovitz, G.; Abu-Ghanem, S.; Livneh, E. PKC eta confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells. *Exp. Cell Res.* **2009**, *315*, 2616–2623. [CrossRef] [PubMed]

38. Raveh-Amit, H.; Hai, N.; Rotem-Dai, N.; Shahaf, G.; Gopas, J.; Livneh, E. Protein kinase C eta activates NF-kappaB in response to camptothecin-induced DNA damage. *Biochem. Biophys. Res. Commun.* **2011**, *412*, 313–317. [CrossRef] [PubMed]

39. Uht, R.M.; Amos, S.; Martin, P.M.; Riggan, A.E.; Hussaini, I.M. The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. *Oncogene* **2007**, *26*, 2885–2893. [CrossRef] [PubMed]

40. Hussaini, I.M.; Carpenter, J.E.; Redpath, G.T.; Sando, J.J.; Shaffrey, M.E.; Vandenberg, S.R. Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. *Neuro Oncol.* **2002**, *4*, 9–21. [CrossRef]

41. Ma, L.; Shan, Y.; Bai, R.; Xue, L.; Eide, C.A.; Ou, J.; Zhu, L.J.; Hutchinson, L.; Cerny, J.; Khoury, H.J.; et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. *Sci. Transl. Med.* **2014**, *6*, 252ra121. [CrossRef] [PubMed]

42. Abu-Ghanem, S.; Oberkovitz, G.; Benharroch, D.; Gopas, J.; Livneh, E. PKC eta expression contributes to the resistance of Hodgkin’s lymphoma cell lines to apoptosis. *Cancer Biol. Ther.* **2007**, *6*, 1375–1380. [CrossRef] [PubMed]

43. Sonnemann, J.; Gekeler, V.; Ahlbrecht, K.; Brischwein, K.; Liu, C.; Bader, P.; Muller, C.; Niethammer, D.; Beck, J.F. Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. *Cancer Lett.* **2004**, *209*, 177–185. [CrossRef] [PubMed]

44. Sonnemann, J.; Gekeler, V.; Sagrauske, A.; Muller, C.; Hofmann, H.P.; Beck, J.F. Down-regulation of protein kinase Ceta potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells. *Mol. Cancer Ther.* **2004**, *3*, 773–781. [PubMed]

45. Ku, B.M.; Yune, Y.P.; Lee, E.S.; Hah, Y.S.; Park, J.Y.; Jeong, J.Y.; Lee, D.H.; Cho, G.J.; Choi, W.S.; Kang, S.S. PKC eta Regulates the TGFbeta3-induced Chondrocyte Differentiation of Human Mesenchymal Stem Cells. *Dev. Reprod.* **2013**, *17*, 299–309. [CrossRef] [PubMed]

46. Hashimoto, Y.; Osada, S.; Ohno, S.; Kuroki, T. A Ca(2+)-independent protein kinase C, nPKC eta: Its structure, distribution and possible function. *Tohoku J. Exp. Med.* **1992**, *168*, 275–278. [CrossRef] [PubMed]

47. Koizumi, H.; Kohno, Y.; Osada, S.; Ohno, S.; Okhawara, A.; Kuroki, T. Differentiation-associated localization of nPKC eta, a Ca(++)-independent protein kinase C, in normal human skin and skin diseases. *J. Investig. Dermatol.* **1993**, *101*, 858–863. [CrossRef]

48. Ikuta, T.; Chida, K.; Tajima, O.; Matsuura, Y.; Iwamori, M.; Ueda, Y.; Mizuno, K.; Ohno, S.; Kuroki, T. Cholesterol sulfate, a novel activator for the eta isoform of protein kinase C. *Cell Growth Differ.* **1994**, *5*, 943–947. [PubMed]

49. Denning, M.F.; Dlugosz, A.A.; Williams, E.K.; Szallas, Z.; Blumberg, P.M.; Yuspa, S.H. Specific protein kinase C isoforms mediate the induction of keratinocyte differentiation markers by calcium. *Cell Growth Differ.* **1995**, *6*, 149–157. [PubMed]

50. Beck, J.; Bohnet, B.; Brugger, D.; Bader, P.; Dietl, J.; Scheper, R.J.; Kandolf, R.; Liu, C.; Niethammer, D.; Gekeler, V. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. *Br. J. Cancer* **1998**, *77*, 87–91. [CrossRef]

51. Shahaf, G.; Rotem-Dai, N.; Koifman, G.; Raveh-Amit, H.; Frost, S.A.; Livneh, E. PKC eta is a negative regulator of AKT inhibiting the IGF-I induced proliferation. *Exp. Cell Res.* **2012**, *318*, 789–799. [CrossRef] [PubMed]

52. Pal, D.; Basu, A. Protein kinase C-eta regulates Mcl-1 level via ERK1. *Cell Signal.* **2017**, *40*, 166–171. [CrossRef] [PubMed]
53. Lee, S.; Schmitt, C.A. The dynamic nature of senescence in cancer. *Nat. Cell Biol.* 2019, 21, 94–101. [CrossRef] [PubMed]
54. Childs, B.G.; Durik, M.; Baker, D.J.; van Deursen, J.M. Cellular senescence in aging and age-related disease: From mechanisms to therapy. *Nat. Med.* 2015, 21, 1424–1435. [CrossRef] [PubMed]
55. Lee, C.S.; Baek, J.; Han, S.Y. The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment. *Molecules* 2017, 22, 1411. [CrossRef] [PubMed]
56. Lujambio, A. To clear, or not to clear (senescent cells)? That is the question. *Bioessays* 2016, 38 (Suppl. 1), S56–S64. [CrossRef]
57. Campisi, J. Aging, cellular senescence, and cancer. *Annu. Rev. Physiol.* 2013, 75, 685–705. [CrossRef] [PubMed]
58. Childs, B.G.; Baker, D.J.; Kirkland, J.L.; Campisi, J.; van Deursen, J.M. Senescence and apoptosis: Dueling or complementary cell fates? *EMBO Rep.* 2014, 15, 1139–1153. [CrossRef] [PubMed]
59. Carnero, A. Markers of cellular senescence. *Methods Mol. Biol.* 2013, 965, 63–81. [CrossRef] [PubMed]
60. Canzian, F.; Gariboldi, M.; Manenti, G.; De Gregorio, L.; Osada, S.; Ohno, S.; Dragani, T.A.; Pierotti, M.A. Expression in lung tumors and genetic mapping of the novel murine protein kinase C eta. *Mol. Carcinog.* 1994, 9, 111–113. [CrossRef] [PubMed]
61. Chida, K.; Murakami, A.; Tagawa, T.; Ikuta, T.; Kuroki, T. Cholesterol sulfate, a second messenger for the eta isoform of protein kinase C, inhibits promotional phase in mouse skin carcinogenesis. *Cancer Res.* 1995, 55, 4865–4869. [PubMed]
62. Chida, K.; Hara, T.; Hirai, T.; Konishi, C.; Nakamura, K.; Nakao, K.; Aiba, A.; Katsuki, M.; Kuroki, T. Disruption of protein kinase C eta results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. *Cancer Res.* 2003, 63, 2404–2408. [PubMed]
63. Doi, S.; Goldstein, D.; Hug, H.; Weinstein, I.B. Expression of multiple isoforms of protein kinase C in normal human colon mucosa and colon tumors and decreased levels of protein kinase C beta and eta mRNAs in the tumors. *Mol. Carcinog.* 1994, 11, 197–203. [CrossRef] [PubMed]
64. Masso-Welch, P.A.; Winston, J.S.; Edge, S.; Darcy, K.M.; Asch, H.; Vaughan, M.M.; Ip, M.M. Altered expression and localization of PKC eta in human breast tumors. *Breast Cancer Res. Treat.* 2001, 68, 211–223. [CrossRef] [PubMed]
65. Lu, H.C.; Chou, F.P.; Yeh, K.T.; Chang, Y.S.; Hsu, N.C.; Chang, J.G. Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. *Pathology* 2009, 41, 626–629. [CrossRef] [PubMed]
66. Brenner, W.; Farber, G.; Herget, T.; Wiesner, C.; Hengstler, J.G.; Thuroff, J.W. Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). *Anticancer Res.* 2003, 23, 4001–4006. [PubMed]
67. Pal, D.; Outram, S.P.; Basu, A. Upregulation of PKCeta by PKCepsilon and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. *Biochim. Biophys. Acta* 2013, 1830, 4040–4045. [CrossRef] [PubMed]
68. Krasnitsky, E.; Baumfeld, Y.; Freedman, J.; Sion-Vardy, N.; Ariad, S.; Novack, V.; Livneh, E. PKCeta is a novel prognostic marker in non-small cell lung cancer. *Anticancer Res.* 2012, 32, 1507–1513. [PubMed]
69. Porter, S.N.; Magee, J.A. PRKCH regulates hematopoietic stem cell function and predicts poor prognosis in acute myeloid leukemia. *Exp. Hematol.* 2017. [CrossRef]
70. Quan, T.; Fisher, G.J. Cloning and characterization of the human protein kinase C-eta promoter. *J. Biol. Chem.* 1999, 274, 28566–28574. [CrossRef] [PubMed]
71. Evdokimova, V.; Tognon, C.; Ng, T.; Sorensen, P.H. Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. *Cell Cycle* 2009, 8, 2901–2906. [CrossRef] [PubMed]

© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).